Sclerostin levels predict cardiovascular mortality in long-term hemodialysis patients: A prospective observational...

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Biochemistry

Background:

• Sclerostin is a key regulator of bone metabolism.
• Emerging evidence suggests sclerostin's role in vascular calcification and cardiovascular health.
• Its significance in patients with chronic kidney disease requiring hemodialysis is not fully understood.

Purpose of the Study:

• To investigate the prognostic value of serum sclerostin levels in hemodialysis patients.
• To assess the association between sclerostin and overall mortality, cardiovascular mortality, and infection-related mortality.
• To explore the combined effect of sclerostin and residual diuresis on cardiovascular outcomes.

Main Methods:

• Prospective observational cohort study.
• Inclusion of 106 hemodialysis patients and 25 healthy controls.
• Serum sclerostin measurement via ELISA, with a five-year follow-up period.

Main Results:

• Hemodialysis patients exhibited significantly higher serum sclerostin concentrations than controls (89.2±40.3 pmol/l vs. 32.8±13.0 pmol/l, p<0.001).
• Elevated sclerostin levels (above median >84 pmol/l) were a significant predictor of cardiovascular mortality (HR: 2.577, p=0.04).
• The combination of high sclerostin and absent residual diuresis was associated with the worst prognosis for cardiovascular events.

Conclusions:

• Serum sclerostin is elevated in hemodialysis patients.
• High sclerostin levels serve as a risk factor for cardiovascular mortality in this population.
• Further research is needed to elucidate sclerostin's role in renal failure and guide potential therapeutic interventions.